Perlecan deficiency causes endothelial dysfunction by reducing the expression of endothelial nitric oxide synthase

Area of Science:

• Vascular Biology
• Extracellular Matrix Biology
• Proteoglycan Research

Background:

• Perlecan is a key heparan sulfate proteoglycan in the vascular wall's subendothelial extracellular matrix.
• Understanding perlecan's function is crucial for vascular health and disease research.

Purpose of the Study:

• To investigate the role of perlecan in regulating vascular tone.
• To determine the impact of perlecan deficiency on endothelial function and nitric oxide production.

Main Methods:

• Utilized a conditional perlecan-deficient mouse model to assess aortic ring isometric force.
• Measured endothelium-dependent and independent relaxation responses to vasoactive agents.
• Quantified endothelial nitric oxide synthase (eNOS) gene and protein expression via real-time PCR and Western blotting.
• Employed small interfering RNA (siRNA) in human aortic endothelial cells to study perlecan knockdown effects on eNOS expression.

Main Results:

• Perlecan-deficient aortas exhibited significantly reduced endothelium-dependent relaxation to acetylcholine.
• Endothelium-independent relaxation to sodium nitroprusside was preserved in perlecan-deficient aortas.
• Both eNOS gene and protein expression were significantly decreased in perlecan-deficient aortas and perlecan siRNA-treated cells.
• Perlecan knockdown in human aortic endothelial cells led to reduced eNOS gene expression.

Conclusions:

• Perlecan deficiency results in endothelial dysfunction, characterized by impaired endothelium-dependent relaxation.
• Reduced eNOS expression is a key mechanism contributing to the observed endothelial dysfunction in perlecan deficiency.
• Perlecan appears to play a significant role in activating eNOS gene expression during normal physiological processes.